Payment overview · 2025
General Payments
$223.85
11 reported records · 9 companies
Healthcare provider profile · identity verified
Misty Sharp Ingram, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · COLLINSVILLE, AL · NPI 1437774080
Verified facts
What the public records show
CMS Open Payments records show Misty Sharp Ingram, CRNP received $223.85 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.31 | 18.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.07 | 14.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $27.04 | 12.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.39 | 10.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.58 | 10.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.44 | 10.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.51 | 9.6% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $14.97 | 6.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.54 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $223.85 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.31 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.07 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $27.04 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.39 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 139 | 38 |
| Omeprazole | Omeprazole | 134 | 37 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 109 | 32 |
| Losartan Potassium | Losartan Potassium | 106 | 39 |
| Lisinopril | Lisinopril | 104 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 30 |
| Trazodone Hcl | Trazodone Hcl | 87 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 27 |
| Azithromycin | Azithromycin | 84 | 75 |
| Buspirone Hcl | Buspirone Hcl | 84 | 28 |
| Metformin Hcl | Metformin Hcl | 83 | 23 |
| Montelukast Sodium | Montelukast Sodium | 81 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 76 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 73 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 22 |
| Topiramate | Topiramate | 70 | 14 |
| Potassium Chloride | Potassium Chloride | 68 | 21 |
| Methylprednisolone | Methylprednisolone | 61 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 59 | 14 |
| Fluconazole | Fluconazole | 59 | 30 |
| Simvastatin | Simvastatin | 59 | 12 |
| Ibuprofen | Ibuprofen | 58 | 18 |
| Carvedilol | Carvedilol | 57 | 13 |
| Clonidine Hcl | Clonidine Hcl | 57 | 13 |
| Ondansetron Odt | Ondansetron | 57 | 34 |
| Prednisone | Prednisone | 52 | 32 |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Celecoxib | Celecoxib | 50 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | 12 |
| Jardiance | Empagliflozin | 43 | suppressed |
| Methocarbamol | Methocarbamol | 43 | suppressed |
| Mupirocin | Mupirocin | 43 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 41 | suppressed |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 15 |
| Meclizine Hcl | Meclizine Hcl | 40 | 15 |
| Cefdinir | Cefdinir | 36 | 28 |
| Meloxicam | Meloxicam | 35 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | suppressed |
| Nystatin | Nystatin | 33 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 32 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Furosemide | Furosemide | 24 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | 12 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | 15 |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Linzess | Linaclotide | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Glipizide | Glipizide | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $223.85 · 11 records | ABBVIE INC. | AIRSUPRA, CAPLYTA, Dexcom G6 Transmitter, FANAPT, MOUNJARO, Ohtuvayre, QULIPTA, REXULTI, TRELEGY ELLIPTA, UBRELVY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error